Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Characterization of the Annonaceous acetogenin, annonacinone, a natural product inhibitor of plasminogen activator inhibitor-1.

Pautus S, Alami M, Adam F, Bernadat G, Lawrence DA, De Carvalho A, Ferry G, Rupin A, Hamze A, Champy P, Bonneau N, Gloanec P, Peglion JL, Brion JD, Bianchini EP, Borgel D.

Sci Rep. 2016 Nov 23;6:36462. doi: 10.1038/srep36462.

2.

Differential influence of selective 5-HT5A vs 5-HT1A, 5-HT1B, or 5-HT2C receptor blockade upon light-induced phase shifts in circadian activity rhythms: interaction studies with citalopram.

Gannon RL, Peglion JL, Millan MJ.

Eur Neuropsychopharmacol. 2009 Dec;19(12):887-97. doi: 10.1016/j.euroneuro.2009.06.011. Epub 2009 Jul 14.

PMID:
19604677
3.

Modulations of the amide function of the preferential dopamine D3 agonist (R,R)-S32504: improvements of affinity and selectivity for D3 versus D2 receptors.

Peglion JL, Poitevin C, Mannoury La Cour C, Dupuis D, Millan MJ.

Bioorg Med Chem Lett. 2009 Apr 15;19(8):2133-8. doi: 10.1016/j.bmcl.2009.03.015. Epub 2009 Mar 9.

PMID:
19324548
4.

Synthesis of benzocyclobutenes by palladium-catalyzed C-H activation of methyl groups: method and mechanistic study.

Chaumontet M, Piccardi R, Audic N, Hitce J, Peglion JL, Clot E, Baudoin O.

J Am Chem Soc. 2008 Nov 12;130(45):15157-66. doi: 10.1021/ja805598s. Epub 2008 Oct 18.

PMID:
18928284
5.

Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity.

Thollon C, Bedut S, Villeneuve N, Cogé F, Piffard L, Guillaumin JP, Brunel-Jacquemin C, Chomarat P, Boutin JA, Peglion JL, Vilaine JP.

Br J Pharmacol. 2007 Jan;150(1):37-46. Epub 2006 Nov 27.

7.

The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis.

Millan MJ, Gobert A, Roux S, Porsolt R, Meneses A, Carli M, Di Cara B, Jaffard R, Rivet JM, Lestage P, Mocaer E, Peglion JL, Dekeyne A.

J Pharmacol Exp Ther. 2004 Oct;311(1):190-203. Epub 2004 May 14.

PMID:
15146031
8.

S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.

Millan MJ, Brocco M, Papp M, Serres F, La Rochelle CD, Sharp T, Peglion JL, Dekeyne A.

J Pharmacol Exp Ther. 2004 Jun;309(3):936-50. Epub 2004 Feb 20.

PMID:
14978196
9.

S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.

Millan MJ, Di Cara B, Hill M, Jackson M, Joyce JN, Brotchie J, McGuire S, Crossman A, Smith L, Jenner P, Gobert A, Peglion JL, Brocco M.

J Pharmacol Exp Ther. 2004 Jun;309(3):921-35. Epub 2004 Feb 20.

PMID:
14978195
10.

S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.

Millan MJ, Cussac D, Gobert A, Lejeune F, Rivet JM, Mannoury La Cour C, Newman-Tancredi A, Peglion JL.

J Pharmacol Exp Ther. 2004 Jun;309(3):903-20. Epub 2004 Feb 20.

PMID:
14978194
11.

Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs.

Vilaine JP, Bidouard JP, Lesage L, Reure H, Péglion JL.

J Cardiovasc Pharmacol. 2003 Nov;42(5):688-96.

PMID:
14576519
12.

In vivo quantification of myocardial dihydropyridine binding sites: a PET study in dogs.

Valette H, Dollé F, Guenther I, Fuseau C, Coulon C, Hinnen F, Péglion JL, Crouzel C.

J Nucl Med. 2002 Sep;43(9):1227-33.

13.

Improvement in the selectivity and metabolic stability of the serotonin 5-HT(1A) ligand, S 15535: a series of cis- and trans-2-(arylcycloalkylamine) 1-indanols.

Peglion JL, Goument B, Despaux N, Charlot V, Giraud H, Nisole C, Newman-Tancredi A, Dekeyne A, Bertrand M, Genissel P, Millan MJ.

J Med Chem. 2002 Jan 3;45(1):165-76.

PMID:
11754589
14.

S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.

Millan MJ, Dekeyne A, Papp M, La Rochelle CD, MacSweeny C, Peglion JL, Brocco M.

J Pharmacol Exp Ther. 2001 Aug;298(2):581-91.

PMID:
11454919
15.
16.

Myocardial kinetics of the (11)C-labeled enantiomers of the Ca(2+) channel inhibitor S11568: an in vivo study.

Valette H, Dollé F, Guenther I, Hinnen F, Fuseau C, Coulon C, Péglion JL, Crouzel C.

J Nucl Med. 2001 Jun;42(6):932-7.

18.

S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.

Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, Audinot V, Adhumeau A, Brocco M, Nicolas JP, Boutin JA, Despaux N, Peglion JL.

J Pharmacol Exp Ther. 2000 Jan;292(1):38-53.

PMID:
10604930
19.
20.

Synthesis and characterization of a 11C-labelled derivative of S12968: an attempt to image in vivo brain calcium channels.

Dollé F, Valette H, Hinnen F, Fuseau C, Péglion JL, Crouzel C.

Nucl Med Biol. 1998 May;25(4):339-42.

PMID:
9639294
21.

Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257.

Thollon C, Bidouard JP, Cambarrat C, Lesage L, Reure H, Delescluse I, Vian J, Peglion JL, Vilaine JP.

Eur J Pharmacol. 1997 Nov 19;339(1):43-51.

PMID:
9450615
22.

S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties.

Millan MJ, Hjorth S, Samanin R, Schreiber R, Jaffard R, De Ladonchamps B, Veiga S, Goument B, Peglion JL, Spedding M, Brocco M.

J Pharmacol Exp Ther. 1997 Jul;282(1):148-61.

PMID:
9223550
23.

5-HT2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists.

Millan MJ, Peglion JL, Lavielle G, Perrin-Monneyron S.

Eur J Pharmacol. 1997 Apr 23;325(1):9-12.

PMID:
9151932
24.

Synthesis of two optically active calcium channel antagonists labelled with carbon-11 for in vivo cardiac PET imaging.

Dollé F, Hinnen F, Valette H, Fuseau C, Duval R, Péglion JL, Crouzel C.

Bioorg Med Chem. 1997 Apr;5(4):749-64.

PMID:
9158874
25.

Sigma ligand S14905 and locomotor activity in mice.

Hascoet M, Bourin M, Payeur R, Lombet A, Peglion JL.

Eur Neuropsychopharmacol. 1995 Dec;5(4):481-9.

PMID:
8998401
26.

[3H](+)S 14297: a novel, selective radioligand at cloned human dopamine D3 receptors.

Newman-Tancredi A, Audinot V, Jacques V, Peglion JL, Millan MJ.

Neuropharmacology. 1995 Dec;34(12):1693-6.

PMID:
8788967
28.
29.

Characterization of potent and selective antagonists at postsynaptic 5-HT1A receptors in a series of N4-substituted arylpiperazines.

Peglion JL, Canton H, Bervoets K, Audinot V, Brocco M, Gobert A, Le Marouille-Girardon S, Millan MJ.

J Med Chem. 1995 Sep 29;38(20):4044-55.

PMID:
7562940
30.

Modulation of mesolimbic dopamine release by the selective dopamine D3 receptor antagonist, (+)-S 14297.

Rivet JM, Audinot V, Gobert A, Peglion JL, Millan MJ.

Eur J Pharmacol. 1994 Nov 24;265(3):175-7.

PMID:
7875234
31.

S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats.

Millan MJ, Audinot V, Rivet JM, Gobert A, Vian J, Prost JF, Spedding M, Peglion JL.

Eur J Pharmacol. 1994 Aug 1;260(2-3):R3-5.

PMID:
7988633
32.

Multidrug-resistance circumvention and inhibition of [h-3] azidopine photolabeling of p-glycoprotein by new dihydropyridine derivatives displaying a low-affinity for calcium channels.

Leonce S, Pierre A, Perez V, Guilbaud N, Krausberthier L, Genton A, Lombet A, Peglion J, Atassi G.

Int J Oncol. 1994 Jun;4(6):1243-50.

PMID:
21567044
33.
34.

In vivo reversal of multidrug resistance by two new dihydropyridine derivatives, S16317 and S16324.

Kraus-Berthier L, Guilbaud N, Peglion JL, Leonce S, Lombet A, Pierre A, Atassi G.

Acta Oncol. 1994;33(6):631-7.

PMID:
7946440
35.

S 15535: a highly selective benzodioxopiperazine 5-HT1A receptor ligand which acts as an agonist and an antagonist at presynaptic and postsynaptic sites respectively.

Millan MJ, Rivet JM, Canton H, Lejeune F, Gobert A, Widdowson P, Bervoets K, Brocco M, Peglion JL.

Eur J Pharmacol. 1993 Jan 5;230(1):99-102.

PMID:
8381359
36.

Ca2+ channel inhibition in a rat osteoblast-like cell line, UMR 106, by a new dihydropyridine derivative, S11568.

Morain P, Peglion JL, Giesen-Crouse E.

Eur J Pharmacol. 1992 Sep 10;220(1):11-7.

PMID:
1385178
37.

The calcium channel antagonist S 11568 causes endothelium-dependent relaxation in canine arteries.

Vilaine JP, Biondi ML, Villeneuve N, Feletou M, Peglion JL, Vanhoutte PM.

Eur J Pharmacol. 1991 May 2;197(1):41-8.

PMID:
1654260
38.

Inhibition of L-type but not T-type calcium channel current by a new dihydropyridine derivative, S11568.

Randle JC, Péglion JL, Renaud JF.

J Cardiovasc Pharmacol. 1991 Feb;17(2):348-50.

PMID:
1709243
39.

Ca2+ channel inhibition by a new dihydropyridine derivative, S11568, and its enantiomers S12967 and S12968.

Randle JC, Lombet A, Nagel N, Abraham C, Aptel H, Peglion JL, Renaud JF.

Eur J Pharmacol. 1990 Nov 6;190(1-2):85-96.

PMID:
1706275

Supplemental Content

Loading ...
Support Center